INDIANAPOLIS, March 9, 2018 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) today announced that Maura Dickler, M.D., a prestigious breast cancer
researcher, will join Lilly Oncology as Vice President of Late
Phase Development on May 7,
2018.
Dr. Dickler is currently the Section Head, Endocrine Therapy
Clinical Research Program at Memorial Sloan Kettering Cancer Center
(MSKCC). She concurrently serves as Associate Member, Breast
Medicine Service, Department of Medicine, MSKCC and Associate
Professor of Medicine, Weill Cornell Medical College, NY. She will
report to Levi Garraway, M.D.,
Ph.D., Senior Vice President, Global Development & Medical
Affairs of Lilly Oncology.
"Dr. Dickler is an internationally recognized oncology leader
with drug development expertise spanning a wide range of
therapeutic modalities," said Garraway. "Moreover, she is an
exceptionally gifted clinician for whom patients are at the center
of everything she does. We are thrilled to have Dr. Dickler join us
at Lilly."
About Maura Dickler,
M.D.
Dr. Dickler graduated from The University of Chicago's Pritzker School of Medicine
and completed her fellowship at MSKCC. She is a clinical researcher
on the Breast Medicine Service at MSKCC, with a research program
focused on developing new therapeutic strategies for the treatment
of women with hormone-receptor positive (HR+) breast cancer. She
has led clinical trials investigating therapeutic agents targeting
several growth factor receptor-signaling pathways important in
breast cancer, including the epidermal growth factor receptor
(EGFR), human epidermal growth factor receptor 2 (HER2), vascular
endothelial growth factor receptor (VEGFR), phosphoinositide
3-kinase (PI3K) and the estrogen receptor pathway. She has also
investigated cyclin-dependent kinase 4 & 6 (CDK4 & 6)
inhibitors targeting the cell cycle.
Dr. Dickler's research and clinical accomplishments have led to
numerous publications and she has served on various committees
including the Breast Committee of The Alliance for Clinical Trials
in Oncology. She has received honors for her clinical care,
including New York Magazine's Best Doctors, Medical Oncology in
2015, 2016 and 2017; Castle Connolly America's Top Doctors; and
Castle Connolly Exceptional Women in Medicine in 2017.
About Lilly Oncology
For more than 50
years, Lilly has been dedicated to delivering life-changing
medicines and support to people living with cancer and those who
care for them. Lilly is determined to build on this heritage and
continue making life better for all those affected by cancer around
the world. To learn more about Lilly's commitment to people with
cancer, please visit www.LillyOncology.com.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
newsroom.lilly.com/social-channels.
C-LLY
Refer to: Carole
Copeland; Carole_Copeland@lilly.com;
317-610-6196
View original content with
multimedia:http://www.prnewswire.com/news-releases/maura-dickler-md-to-become-vice-president-of-late-phase-development-at-lilly-oncology-300611499.html
SOURCE Eli Lilly and Company